Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The Achieve-3 trial, funded by Eli Lilly, studied more than 1,500 adults with type 2 diabetes from 131 medical research centres and hospitals in Argentina, China, Japan, Mexico and the US
doi:10.1111/dom.13339 37
Injection site reactions (erythema, edema, mild discomfort) occur in 815% of reported cases and typically resolve within 13 days
The available animal models can be characterized as dietary, genetic or as a combination of these two
at initiation, dose change and cessation)
Reaven, Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans
US$ 26.76
US$ 29.83
US$ 20.14
US$ 29.65
US$ 20.00
